Quince Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
A novel drug-device therapy for ataxia-telangiectasia is nearing pivotal phase 3 readout, focusing on children ages 6–9. Safety data are robust, and the trial is powered to detect clinically meaningful improvements. NDA filing is targeted for late 2024, with commercial plans leveraging a national infusion network.
-
eDSP, an encapsulated dexamethasone therapy, is advancing through a pivotal phase III trial in ataxia-telangiectasia, with top-line results expected in Q1 2026. The platform shows strong safety, regulatory momentum, and blockbuster commercial potential, with DMD as the next target indication.
-
AIDE technology enables monthly corticosteroid therapy with reduced toxicity, targeting rare diseases like ataxia telangiectasia. Phase III trial enrollment is complete, with data expected in Q1 2026 and strong commercialization plans in place.
-
A novel red blood cell encapsulation platform enables chronic steroid therapy for rare diseases, with phase III data in Ataxia Telangiectasia expected Q4. The approach shows strong safety, promising efficacy, and billion-dollar market potential.
-
A novel red blood cell-encapsulated dexamethasone therapy aims to address the unmet need in ataxia-telangiectasia, with a pivotal Phase 3 trial nearing full enrollment and top-line data expected by year-end. The platform shows strong safety, significant market potential, and expansion plans for other rare diseases.
-
A novel red blood cell-encapsulated dexamethasone therapy for AT has shown significant efficacy in slowing neurological decline in young patients, with a strong safety profile and minimal steroid toxicity. The pivotal NEAT phase 3 trial is underway, with top-line results expected in late 2025.
Fiscal Year 2024
-
A pivotal phase III trial for EryDex in pediatric A-T is underway, with top-line results expected in Q4 2025 and a $1 billion market opportunity. The technology enables monthly steroid delivery with reduced side effects, and DMD is targeted as the next indication.
-
EryDex is advancing in a pivotal phase III trial for ataxia telangiectasia, targeting a $1B+ rare disease market with no approved therapies. The platform's safety and efficacy support expansion into multiple indications, with strong leadership and financial runway into 2026.